Hepatic Fibrosis Test YRA317 // YRA321

The Hepatic Fibrosis Test YRA317 // YRA321 is an essential diagnostic tool for early detection and management of hepatic fibrosis. This product is designed to assess liver fibrosis levels, enabling healthcare professionals to implement early interventions that can reverse or delay the development of serious liver conditions such as cirrhosis. Compatible with Chemiluminescence Immunoassay Analyzers YR06389 and YR06390, it offers a reliable and efficient way to improve patient outcomes and quality of life.

Market Price

The Hepatic Fibrosis Test is competitively priced in the market, with a range typically starting from $200 to $500 per box, depending on the distributor and quantity ordered. Bulk purchases tend to offer significant discounts, making it an affordable option for medical institutions and laboratories. For precise pricing tailored to your needs, we recommend generating a quote through the Kalstein Plus platform.

Frequently Asked Questions

1. What parameters are tested in the Hepatic Fibrosis Test?
The test evaluates critical markers such as PIIINP, CIV, LN, HA, and CG, which are key indicators of liver fibrosis.

2. Is this test suitable for all patient demographics?
Yes, this test is applicable to a broad range of patients, subject to professional medical advice.

3. What are the storage conditions for the test kits?
The test kits should be stored at 2-8°C to maintain their effectiveness.

Advantages and Disadvantages

The Hepatic Fibrosis Test offers several advantages. It enables early detection of liver fibrosis, potentially reversing the condition before it progresses to cirrhosis. Its compatibility with multiple analyzers ensures flexibility in testing procedures. However, a potential disadvantage is the need for specialized equipment for analysis, which may not be available in all healthcare settings.

Usage in the Field

Clinicians typically use this test in hospital laboratories or specialized diagnostic centers. The process involves collecting a patient sample, which is then processed using the compatible Chemiluminescence Immunoassay Analyzers. The results help in guiding treatment options and monitoring the effectiveness of therapy over time.

Recommendations

For optimal use, it is recommended that healthcare providers receive proper training in operating the Chemiluminescence Immunoassay Analyzers. Regular calibration and maintenance of the equipment can ensure accurate results. Additionally, storing the test kits under recommended conditions is crucial for ensuring their integrity and performance.

Features

• Early detection and monitoring of hepatic fibrosis
• Compatible with YR06389 and YR06390 analyzers
• Efficient use in clinical settings
• Comprehensive testing for multiple liver fibrosis markers
• CE, ISO13485, and FSC certified

Technical Specifications